RBX2660 Shows Consistent Safety, Efficacy for C. Diff

(MedPage Today) -- New clinical trial data presented at the Digestive Disease Week meeting suggest that an investigational microbiota-based live biotherapeutic (RBX2660) leads to a consistent reduction in the risk of Clostridioides difficile recurrence...